|
CASP8 hypermethylation |
Frequency of 19% and associated with RASSF1A methylation [88] |
|
GLIPR1/RTVP hypomethylation |
Frequency of 87.5%, results in overexpression [89] |
| Global hypomethylation |
Results in genome instability in tumour cells [90, 91]. |
| Gain of methylation at 6p22.1, 6p21.32 and 11q13.5 |
Biomarker for WT, can be detected in the circulation of patients [92] |
|
HACE1 hypermethylation |
Frequency of 73% [93] |
| Hypermethylation of a CTCF binding site downstream of WT1
|
Correlated with high WT1 expression [94] |
| Hypermethylation of protocadherin cluster at 5q31 |
Results in expression loss of these proteins at the cell surface [95] |
| LOI 11p15 |
Frequency of 69%, results in overexpression of IGF2 and down-regulation of H19 [29, 36, 96] |
| P16 hypermethylation |
Frequency of 23% [97] |
|
RASSF1 hypermethylation |
Frequency of 54% [98] |
|
WT1-antisense transcript hypomethylation |
Results in biallelic expression [99] |
